Biologic therapy for psoriasis: The tumor necrosis factor inhibitors - Infliximab and etanercept

被引:0
|
作者
Weinberg, JM
机构
[1] St Lukes Roosevelt Hosp, Dept Dermatol, New York, NY 10025 USA
[2] Beth Israel Med Ctr, Dept Dermatol, New York, NY 10003 USA
来源
CUTIS | 2003年 / 71卷 / 01期
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
This article has been peer reviewed and approved,by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine Review date December 2002, December. This activity has been planned and implemented in accordance with the Essential Area's and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship, of Albert Einstein College of Medicine and :Quadrant HealthCom, Inc. The Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Albert Einstein College of Medicine designates this educational activity for a in category, 1 credit toward the AMA Physician's Recognition. Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. This activity has been planned and produced in accordance with ACCME Essentials.
引用
收藏
页码:25 / 29
页数:5
相关论文
共 50 条
  • [21] Tumor Necrosis Factor Inhibitors and Myocardial Infarction in Psoriasis Reply
    Armstrong, April W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (10): : 1076 - 1076
  • [22] Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept?
    Ehlers, S
    CLINICAL INFECTIOUS DISEASES, 2005, 41 : S199 - S203
  • [23] Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
    Lee, JH
    Slifman, NR
    Gershon, SK
    Edwards, ET
    Schwieterman, WD
    Siegel, JN
    Wise, RP
    Brown, SL
    Udall, JN
    Braun, MM
    ARTHRITIS AND RHEUMATISM, 2002, 46 (10): : 2565 - 2570
  • [24] Biological therapy for psoriasis: An overview of infliximab, etanercept, efalizumab and alefacept
    Tutrone, WD
    Saini, R
    Weinberg, JM
    IDRUGS, 2004, 7 (01) : 45 - 49
  • [25] Evidences that anti tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages but not lymphocytes in RA joints.
    Ulfgren, AK
    Catrina, A
    Klint, EA
    Trollmo, T
    Klareskog, L
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S373 - S373
  • [26] ECONOMIC EVALUATION OF BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PSORIASIS: ETANERCEPT COMPARED TO ADALIMUMAB AND INFLIXIMAB
    Webber, J. M.
    Lloyd, A. C.
    Lebmeier, M.
    Conway, P.
    VALUE IN HEALTH, 2009, 12 (07) : A456 - A456
  • [27] Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases
    Buckley, Lisa H.
    Xiao, Rui
    Perman, Marissa J.
    Grossman, Andrew B.
    Weiss, Pamela F.
    ARTHRITIS CARE & RESEARCH, 2021, 73 (02) : 215 - 220
  • [28] Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab
    Al-Mutairi, Nawaf
    Nour, Tarek
    Al-Rqobah, Duha
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) : 625 - 629
  • [29] Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
    Megumi Kishimoto
    Mayumi Komine
    Koji Kamiya
    Junichi Sugai
    Aya Kuwahara
    Makiko Mieno
    Mamitaro Ohtsuki
    Dermatology and Therapy, 2023, 13 : 1347 - 1360
  • [30] Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
    Kishimoto, Megumi
    Komine, Mayumi
    Kamiya, Koji
    Sugai, Junichi
    Kuwahara, Aya
    Mieno, Makiko
    Ohtsuki, Mamitaro
    DERMATOLOGY AND THERAPY, 2023, 13 (06) : 1347 - 1360